Beta blockers in the management of chronic kidney disease  by Bakris, G.L. et al.
Beta blockers in the management of chronic
kidney disease
GL Bakris1, P Hart2 and E Ritz3
1Department of Medicine, Hypertension Center, Endocrine Division, University of Chicago School of Medicine, Chicago, Illinois, USA;
2Department of Medicine, Cook County Hospital, Chicago, Illinois, USA and 3Department of Medicine, Division of Nephrology,
University of Heidelberg, Heidelberg, Germany
The sympathetic nervous system modulates renal function
through its receptors namely b1 (cardiac output and renin
release), a1 (systemic and renovascular constriction), and b2
renovascular dilation. Sympathetic overactivity is commonly
seen in chronic kidney disease (CKD) and is an important
contributor to increasing the risk of cardiovascular events
as well as increasing renal disease progression. Recent
evaluations of drug use in people with CKD shows a
remarkably low percentage of patients receiving b-blockers,
especially in more advanced stage CKD when cardiovascular
risk is higher. This is in large part due to tolerability of these
agents. Moreover, water-soluble b-blockers such as atenolol
and metoprolol are dialyzable and require supplementation
to avoid exacerbation of arrhythmias following dialysis.
Newer vasodilating b-blockers have better tolerability and
different effects on renal hemodynamics as well as metabolic
variables. These effects are related to the relative a1-blocking
effect of agents such as carvedilol and labetolol, with
carvedilol having relatively greater a-blocking effects. Few
studies evaluate b-blockers on cardiovascular risk in CKD
patients. Studies with carvedilol demonstrate attenuated
increases in albuminuria as well as reduction in
cardiovascular events in CKD patients with hypertension. This
paper reviews the animal and clinical trial data that evaluate
b-blockers in CKD highlighting the vasodilating b-blockers.
It is apparent that greater use of this drug class for blood
pressure control would further enhance reduction of risk of
heart failure, the most common cause of death in the first
year of starting dialysis.
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Given the high prevalence of cardiovascular disease in people
with chronic kidney disease (CKD) and the clear benefits of
mortality reduction observed for most b-blockers in clinical
trials, they are relatively underused in CKD patients. The
reasons for this relative lack of b-blocker use as well as the
role of newer subclasses of this antihypertensive group in
people with CKD are discussed.
In order to understand the rationale for use of b-blockers
in patients with CKD, it is useful to review some background
information on sympathetic overactivity in such patients as
well as elucidate its role in the genesis of hypertension and
progression of kidney disease as well as potentially of
cardiovascular complications. Experimental evidence focused
on the role of the sympathetic system will be initially
presented followed by data from clinical studies and trials.
Studies by DiBona1 identified chemoreceptors and
baroreceptors in the kidney. In models of experimental renal
damage, Campese and Krol2 and Ye et al.3 documented that
the activation of afferent signals emanating from damaged
kidneys, travel via the spinal cord into the hypothalamus,
where local catecholamine turnover is upregulated, leading
to increased efferent sympathetic nerve traffic into the
periphery.
The activation of the hypothalamic centers which occurs
in response to afferent signals has been proven by experi-
ments with sections of the dorsal roots (rhizotomy), which
abrogated hypertension in subtotally nephrectomized rats.4
Such afferent signals were seen with different types of kidney
injury; most impressive was the observation that injection of
as little as 20 ml phenol raised blood pressure; this hyper-
tension was abrogated several weeks later by resection of the
phenol-treated kidney.5 Sympathetic overactivity in kidney
disease is involved in the genesis of hypertension, in the
progression of kidney disease, and in the cardiac complica-
tions of kidney failure. The role of the sympathetic nervous
system (SNS) in the progression of nephropathy has been
documented by observations in subtotally nephrectomized
rats in which nonhypotensive doses of b-blockers amelio-
rated the development of glomerulosclerotic and cardiac
lesions.6 Similar observations concerning kidney disease
progression were noted with the central sympathicoplegic
agent moxonidine.7 Additionally, moxonidine also reduced
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albumin excretion in patients with type I diabetes, despite
causing no change in ambulatory blood pressure.8,9
In a separate model of kidney disease (spontaneously
hypertensive rats with adriamycin nephropathy), a-/b-
blocker carvedilol decreased systolic blood pressure, de-
creased renal vascular resistance (RVR), and significantly
increased renal blood flow (RBF). Moreover, it significantly
decreased interstitial infiltration in the early phase of the
study, slowed development of interstitial fibrosis and tubular
atrophy, and decreased blood vessel changes. These changes
strongly correlated with slowed nephropathy progression as
well as decreases in proteinuria. The addition of captopril to
carvedilol improved its effects, especially on prevention of
tubulointerstitial changes.10
In subtotally nephrectomized rats with known micro-
angiopathy, b-blockers increased the capillary density in the
heart.11 This is an important observation, as b-blockers
clearly improve cardiac function and reduce cardiovascular
events in hemodialyzed patients.12
In models of chronic renal damage, norepinephrine (NE)
content was decreased, yet increased NE release was noted
upon stimulation of renal nerves.13 This is consistent with
increased NE discharge from reduced numbers of sympa-
thetic nerves, possibly because of partial denervation from
incipient polyneuropathy. Patchy denervation from auto-
nomic polyneuropathy with denervation supersensitivity to
catecholamines may also be relevant in the heart of uremic
patients.14 These observations may explain, at least in part,
the propensity for sudden death,15 a frequent cause of death
in dialysis patients, and the benefit derived from treatment
with b-blockers.12,14
Further abnormalities of the sympathetic system in renal
failure include reduction of b- and a-receptor responsive-
ness.16–18 Direct evidence of sympathetic overactivity was
provided using the methodological gold standard of micro-
neurography of the sural nerve in hemodialyzed patients,19 in
patients with advanced renal failure,20 and even in the earliest
stage of renal disease, that is, patients with polycystic kidney
disease despite no reduction in glomerular filtration rate
(GFR).21 The role of the damaged kidney in causing
sympathetic overactivity is illustrated by the observation that
sympathetic activity is completely normal in hemodialyzed
patients with bilateral nephrectomy.19 Conversely, sympa-
thetic overactivity is still present in renal allograft recipients
and normalizes when their own shrunken kidneys are
removed.22
THE USE OF b-BLOCKERS IN CKD PATIENTS
As there is overwhelming evidence for sympathetic over-
activity in patients with kidney disease, coronary heart
disease and heart failure (HF) are the most common causes
of death in these patients.23 This may be due to inadequate
treatment, as demonstrated by a recent study in which
b-adrenergic blockade was used in fewer than 30% of
patients on hemodialysis.24 This is surprising, as b-blockers
interfere with the deleterious actions of the SNS on cardiac
end points,14 and are well-established, evidence-based
therapy for reducing cardiovascular risk in hypertension25
and after myocardial infarction.12,26
Observational studies suggest definite survival benefits
derived from the use of b-blockers in patients with severe
renal disease.27,28 Furthermore, in a prospective, randomized
study in hemodialyzed patients with HF, Cice et al.12
documented an impressive and significant decrease in death
and hospitalization rates attributable to cardiovascular causes
in patients on carvedilol compared to placebo (Figure 1).
Nevertheless, b-blockers are inadequately used in patients
with CKD, especially those with the most severe renal
failure.29 For example, the United States Renal Data System
Dialysis Morbidity and Mortality Study found that only
20% of chronic dialysis patients were receiving b-blocker
therapy.24 In another study, only 24% of patients with esta-
blished coronary heart disease were treated with b-blockers.30
A similar trend occurs in the predialysis patients.31 One
reason for this underutilization may be fear of adverse
hemodynamic effects on renal physiology or on glycemic
control in patients with diabetes.
b-blockers vary significantly in their pharmacologic
properties. These differences may determine how well an
agent will work and how tolerable it will be in patients with
CKD. Pharmacological properties including lipid solubility,
cardioselectivity and routes of excretion, and the presence of
adjunctive properties such as vasodilatory, antioxidant, and
calcium-blocking activity will all influence the effect of the
agent. Metabolic factors including lipoprotein and serum
potassium levels and glycemic control may also respond
differently to each b-blocker. This review will discuss the
different properties and effects of several commonly used
b-blockers in the management of CKD: propranolol, meto-
prolol, atenolol, labetalol, and carvedilol.
PHARMACOLOGIC PROPERTIES OF b-BLOCKERS
Controlling hypertension is a mainstay in the management
of CKD. Table 1 displays the pharmacologic and renal
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Figure 1 | Kaplan–Meier curve for all-cause mortality during 24-
month follow-up in hemodialysis patients with cardiomyopathy
according to the use of carvedilol. Used with permission.12
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hemodynamic properties of several b-blockers that have been
used to lower blood pressure in hypertensive patients with
diabetic and nondiabetic renal impairment.32–42 Lipophilic
agents undergo extensive first-pass hepatic metabolism with
relatively little being excreted unchanged in the urine.
Hydrophilic agents are excreted primarily by the kidneys
and require dose adjustment in patients with end-stage renal
disease (ESRD). Hydrophilic agents may yield low blood
levels due to poor absorption after oral administration.43,44
b1-selective blockers are cardio-specific and result in reduced
cardiac output, blood pressure, and heart rate. b1-/b2-
blockers antagonize the effects of catecholamine stimulation
on b-adrenergic receptors in resistance vessels as well as the
myocardium. b2-blockade has been shown to be particularly
important in mediating the proarrhythmic effect of NE.45
However, inhibition of b2-vasodilation leaves the reflex a1-
mediated vasoconstrictor response to arterial underfilling
unopposed in the face of decreased blood pressure or cardiac
output. In general, the effects of b-blockade are amplified by
reduction of plasma renin release through inhibition of
b-adrenergic receptors located in the renal juxtaglomerular
apparatus.37
The addition of a1-inhibiting activity to b-adrenergic
antagonists blocks reflex vasoconstriction, and may also
increase blood flow to skeletal muscle, thereby improving
glucose availability and disposal.46 Whereas both nonselective
and b1-selective blockers can increase insulin resistance,
the addition of sufficient a1-blocking activity may
improve insulin sensitivity in both diabetic and nondiabetic
patients.46
b1- and a1-stimulation have opposite effects on specific
enzymes involved in lipid metabolism. Whereas b1-selective
and -nonselective b-blockers tend to increase blood levels of
triglycerides and lower levels of high-density lipoprotein
cholesterol, a1-blockers can lower triglycerides and raise
high-density lipoprotein cholesterol levels.46 Consequently,
the addition of a1-blocking activity to certain b-blockers may
impact both diabetes and arteriosclerotic cardiovascular
disease by promoting better glycemic control with less
compensatory hyperinsulinemia and fewer proatherogenic
changes in serum lipids.38,39
Nonselective b-blockers (as opposed to b1-selective
blockers) may also promote hyperkalemia in patients with
ESRD, especially after exercise, and in patients taking
mineralocorticoid receptor blockers. The risk is higher in
patients with acidosis and patients with tubulointerstitial
disease and can be reduced by administering loop diuretics.
a1-Blockade protects against increases in serum potassium
levels.24,47,48 CKD is associated with increased oxidative
stress.49 Adjunctive antioxidant activity may help b-blockers
protect cell membrane constituents against damage by
oxygen-free radicals and has been shown to attenuate
microalbuminuria.50,51 b-blockers in general reduce urinary
sodium excretion, primarily as a result of lowered blood
pressure, but their adjunctive calcium-blocking activity may
attenuate this antinatriuretic effect, thereby leading to a
reduction in sodium retention.52 a1-Blockade improves RBF
and enhances sodium excretion.45
EFFECTS ON KIDNEY FUNCTION
The SNS exerts important control over normal renal function
and plays a key role in the development and progression of
CKD. The renal vasculature is richly innervated with
sympathetic nerves.53 Adrenergic receptors located in the
pre- and postglomerular arterioles regulate capillary blood
flow and pressure by differential vasomotor tone (renovas-
cular autoregulation) in order to maintain a constant rate of
GFR.37 Afferent arterioles normally constrict to protect
glomerular capillaries from acute increases in blood pressure;
in the presence of CKD, efferent arterioles constrict more
than afferents, which increases intraglomerular pressure in
order to sustain adequate overall ultrafiltration at the expense
of RBF, thereby increasing the filtration fraction.
Increased SNS activity increases the release of NE from
presynaptic sympathetic neurons and epinephrine from the
adrenal medulla. Presynaptic b2-receptors further augment
the release of NE at synaptic junctions. Postsynaptic
sympathetic neurons innervate the muscular layer of
Table 1 | Pharmacologic properties of b-blockers
Propranolol Metoprolol Atenolol Labetalol Carvedilol
Lipophilic Y Y N Y Y
Nonselective (b1/b2) Y N N Y Y
Cardioselective (b1) N Y Y N N
a1-blockade N N N Y Y
Insulin sensitivity k k k 2 m
Serum triglycerides m m m 2 k
Serum HDL cholesterol k k k 2 m
Hyperkalemia in ESRD Y N N Y N
Renal effects in CKD
RVR m k 2 2 k
RBF k 2 2 2 m
GFR k 2 2 2 m
m, increases with use of drug; k, decreases with use of drug; 2, remains the same with use of drug; CKD, chronic kidney disease; ESRD, end-stage renal disease;
GFR, glomerular filtration rate; HDL, high-density lipoprotein; N, no; RBF, renal blood flow; RVR, renal vascular resistance; Y, yes.
Sources:32–42
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resistance vessels controlling systemic and local circulations.
NE stimulation of a1-adrenergic receptors in vascular smooth
muscle results in an increase in renal as well as peripheral
vascular resistance.53 b1-activation stimulates cardiac output
through its effects on myocardial contractility, and subse-
quent blood pressure fluctuations modulate RBF as a
function of cardiac output.
As discussed above, increased sympathetic activity has
been reported consistently in patients with moderate renal
failure as well as in those with ESRD undergoing renal
dialysis. The level of sympathetic activity is an independent
predictor of total as well as cardiovascular mortality in
patients with ESRD.19,54
Nonselective b-blockers
b-blockers have traditionally been a cornerstone of anti-
hypertensive therapy. However, nonselective b-blockers, such
as propranolol, generally decrease GFR and RBF by lowering
cardiac output, thereby reflexively increasing SNS activity
and raising systemic and RVR via a1-receptors. In addition,
blocking b2-vasodilation leaves a1-vasoconstriction unop-
posed.37 These effects could potentially exacerbate established
renal dysfunction in hypertensive patients.
In persons with normal renal function, b-blockers
produce no important effect on renal perfusion or glomer-
ular filtration and are not associated with increases in serum
creatinine or blood urea nitrogen levels.55,56 However, acute
dosing with many b-blockers can produce minor decreases in
GFR, presumably as a desirable consequence of the reversal of
glomerular hypertension. In parallel, a decrease of urinary
sodium excretion is observed.57 The nonselective b-blocker
propranolol diminishes renal perfusion by lowering cardiac
output and renal perfusion pressure, thereby stimulating
reflex a1-vasoconstrictor activity while blocking b2-mediated
vasodilation. Most studies have shown that the chronic
administration of propranolol results in the reduction of RBF
and GFR.55
Cardioselective b-blockers
The b1-selective blockers metoprolol and atenolol were the
first blood pressure-lowering agents to be used in studies
with patients with renal disease, specifically diabetic nephro-
pathy, with dramatically beneficial effects on the rate of
decline of renal function.58,59 Today, b-blockers are recom-
mended as antihypertensive agents in patients with CKD.60
The b1-cardioselective blockers such as metoprolol and
atenolol have been studied in patients with essential
hypertension and normal renal function, hypertensive and
diabetic nephropathy, and ESRD with dialysis or transplanta-
tion. A number of small studies have consistently demon-
strated that neither metoprolol nor atenolol produce
significant reduction in GFR or RBF while effectively
lowering blood pressure in patients with essential hyper-
tension, although both can increase RVR.61–65 In patients
with renovascular hypertension, lowering blood pressure
with metoprolol has been associated with a fall in plasma
renin activity.66 Lowering blood pressure with atenolol in
patients with microalbuminuria owing to diabetic nephro-
pathy has been shown to prevent the usual progression to
macroalbuminuria.67
In patients with impaired renal function, antihypertensive
therapy with metoprolol has beneficial hemodynamic effects,
including a significant reduction in RVR.68 In a clinical trial
of metoprolol plus hydralazine and diuretics in patients with
diabetic nephropathy, the rate of decline in GFR and increase
in albuminuria was significantly reduced compared to the
pretreatment control period.56 Studies with metoprolol and
atenolol in patients with ESRD on chronic dialysis or after
renal transplantation have demonstrated no adverse effects
on renal hemodynamics.69–71 However, although atenolol
needs to be reduced by one-half to three quarters of its
normal dose owing to diminished renal clearance, metoprolol
dosing does not need to be altered, even though one of its less
active metabolites may accumulate.72,73 One study reported,
however, that long-term atenolol therapy in renal transplant
recipients was associated with a significant increase in urinary
protein excretion, but whether this resulted from progressive
transplant nephropathy or from the drug per se remains
unresolved.74 In patients on long-term maintenance hemo-
dialysis with dilated cardiomyopathy, left ventricular size and
function improved and levels of atrial natriuretic and brain
natriuretic peptides decreased following 4 months of
treatment with metoprolol.75
How does the renoprotective effect of b-blockers compare
with that of angiotensin-converting enzyme (ACE) inhibi-
tors? Both metoprolol and atenolol have been compared to
ACE inhibitors in patients with CKD. In both diabetic and
nondiabetic patients, the rate of GFR decline and progression
of albuminuria were attenuated to a greater extent by
antihypertensive therapy with an ACE inhibitor than by
metoprolol or atenolol.76–80 The African American Study of
Kidney Disease and Hypertension compared the long acting,
once daily formulation of metoprolol, the ACE inhibitor,
ramipril, and the calcium channel blocker, amlodipine in
1094 Black subjects with hypertensive nephropathy (GFR
20–65 ml/min per 1.73 m2) followed for a mean of 4 years.81
The primary analysis of the GFR slope did not establish a
definitive difference among the three agents. Significant
benefits were seen, however, with ramipril compared to
metoprolol and amlodipine on the clinical composite out-
come of decline of GFR, ESRD, and death. The results of the
secondary analyses indicated that ramipril treatment slowed
the progression of hypertensive kidney disease to a greater
extent than either once daily metoprolol or amlodipine. The
once daily metoprolol-treated patients had a significantly
lower rate of ESRD or death than those treated with
amlodipine.81
Vasodilating b-blockers
Lowering blood pressure with nonselective (propranolol) or
selective (metoprolol, atenolol) b-blockers is associated with
compensatory stimulation of the SNS and renin–angiotensin
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systems, leading to elevated NE and renin levels. Subsequent
activation of vascular a-adrenergic receptors results in an
increase in systemic as well as RVR. Vasoconstriction is
further exacerbated with nonselective b-antagonists because
of the blockade of b2-mediated vasodilation. It has been
known for a long time that propranolol increases RVR and
reduces RBF and GFR.59,82 Conversely, a1-blockers such as
prazosin and doxazosin enhance renal perfusion.59 In
addition, whereas b-blockers reduce insulin sensitivity and
promote proatherogenic lipoprotein changes, a1-blockers
have the opposite effect.46 Consequently, nonselective
b-blockers with adjunctive a1-blocker activity have been
developed that attenuate renal nerve activity and could
preserve RBF and GFR. Two such agents, labetalol and
carvedilol, have been evaluated in hypertensive patients with
and without renal impairment.
Labetalol, a nonselective b-antagonist with a1-inhibiting
activity (b/a ratio estimated to be between 3:1 and 7:1) has
been available for clinical use since the mid-1980s.58,59,83 In
spite of this long duration of availability, there is very little
data available on renal outcomes or hemodynamics with this
agent. Moreover, in hypertensive patients labetalol has
yielded conflicting results. Five studies have been reported,
which included 81 patients with normal renal function and
six patients with impaired renal function. A fall in RVR led to
increased RBF in one placebo-controlled study of 24 patients
with normal renal function.41 Another study in 17 patients
confirmed a decrease in RVR in subjects with normal renal
function (n¼ 11), but inconsistent responses were found in
those with more impaired renal function (n¼ 6).84 By
contrast, in 18 patients with essential hypertension labetalol
diminished RBF and GFR by 20%85 Two studies in patients
with normal renal function, one including 17 patients and
the other including 11 patients, found no significant effect of
labetalol on GFR, RBF, or body fluid volumes.36,86
The effects of labetalol on carbohydrate and lipid
metabolism have also been evaluated in small studies.
Labetalol administration resulted in a variable increase in
serum glucose levels without a measurable effect on
circulating insulin levels.87–89 Several authors report a lack
of significant changes in cholesterol or triglyceride le-
vels,40,90,91 whereas another group observed a slight decrease
in high-density lipoprotein cholesterol levels.88 Labetalol has
been used as antihypertensive therapy in patients with severe
chronic renal failure. Although this drug is removed by
dialysis, the procedure does not significantly increase its total
body clearance.92 A disturbing side effect of labetalol in
patients on hemodialysis or after renal transplantation is
serious hyperkalemia.93,94
Carvedilol is a nonselective vasodilating b-adrenergic
antagonist with a1-blocking activity (b/a ratio estimated to
be approximately 7:1).95 In addition, carvedilol has anti-
oxidant activity.96,97 The renal effects of carvedilol have
been documented in a number of clinical trials involving
patients with the following conditions: essential hyperten-
sion, renal hypertension, hypertension with evidence of CKD,
hemodialysis, renal transplantation, congestive HF, and
hypertension with diabetes. Carvedilol was administered for
4 weeks to 20 patients with mild-to-moderate essential
hypertension in a randomized, double-blind, placebo-con-
trolled study.96 Despite the therapeutic lowering of blood
pressure, RBF and GFR remained unchanged, whereas RVR
fell by 13%.96 In a longer-term trial, 10 patients with mild-
to-moderate hypertension were treated for an average of
17 weeks: there were no changes in RBF or GFR and a
significant decrease in RVR.98
The efficacy and safety of carvedilol in lowering blood
pressure has been established in several clinical trials of
patients with CKD. In doses that reduced systolic blood
pressure by an average of 22 mmHg given over 2–4 weeks,
carvedilol caused no increase in serum creatinine or blood
urea nitrogen levels.99 In another study, carvedilol, alone or
in combination with a diuretic, was evaluated in 52 patients
with either renal hypertension or essential hypertension
accompanied by renal failure.100 In the group on carvedilol
monotherapy, blood pressure decreased significantly from
166/102 to 150/94 mmHg and in the combined group, the
blood pressure decreased significantly from 175/103 to 142/
85 mmHg. Serum creatinine levels were not worsened,
despite such major reductions in blood pressure.
A pharmacokinetic study found that in CKD, renal
clearance of carvedilol is reduced by approximately 70%,
but the mean 24-h plasma concentration–time curves for the
parent drug and its major metabolites did not differ
significantly between patients with essential hypertension
and normal renal function and those with renal insuffi-
ciency.101 Carvedilol does not accumulate during continuous
daily administration. Because it is 96% protein bound it does
not cross the dialysis membrane.102,103 A study of 15 ESRD
patients with moderate hypertension receiving chronic
dialysis treated with carvedilol for 12 weeks found no relevant
changes in major pharmacokinetic parameters. The max-
imum carvedilol blood concentration (Cmax), the time to
Cmax, and the area under the time–concentration curve during
long-term treatment were all within the range observed in
normal persons.104 Importantly, in contrast to propranolol
and labetalol, serum potassium levels during exercise did not
increase in hemodialysis patients on carvedilol.105
Hypertension adversely affects renal allograft survival, and
effective blood pressure control is important to improve
outcomes. Cyclosporin A, which is frequently used to reduce
renal allograft rejection, is known to increase blood pressure
and RVR while decreasing RBF and GFR.106 Carvedilol
increases cyclosporin A blood levels by 20% so that careful
dose regulation of the antirejection agent is required.107
Conversely, carvedilol has been shown to reduce the oxidative
stress and subsequent upregulation of profibrotic cytokines
that occur in renal transplant patients receiving cyclosporin
A.108 Carvedilol was compared with metoprolol in a
randomized crossover study involving 12 renal allograft
recipients on cyclosporin A. These patients had hypertension
and chronic stable graft rejection. Adequate blood pressure
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control was obtained with both b-blockers, but carvedilol
resulted in an increase in RBF and a decrease in RVR.106
HF may be encountered frequently in patients with CKD,
as both conditions are closely linked to common underlying
factors including hypertension, diabetes, and arteriosclerosis.
HF can also exacerbate renal dysfunction by reducing cardiac
output and stimulating SNS and renin–angiotensin system
overactivity.109 Because of its pharmacological properties, the
renal effects of carvedilol have been investigated in patients
with HF and normal renal function. A randomized, placebo-
controlled comparison was performed during 6 months of
treatment with either carvedilol or metoprolol in 14 patients
with moderately severe HF (New York Heart Association
Class III), severe left ventricular systolic dysfunction (ejection
fraction 16%), and no evidence of significant kidney
impairment.110 Although the ejection fraction increased
comparably with both drugs, only carvedilol improved RBF
and GFR. A subsequent randomized clinical trial compared
carvedilol and enalapril in 572 patients with chronic left
ventricular dysfunction and mild symptoms of HF (approxi-
mately 65% of patients were classified as NYHA Class II) for
18 months. Enalapril alone, carvedilol alone, and the
combination of carvedilol and enalapril were all well
tolerated. In this study, there were no significant differences
among the three study arms with regard to either blood
pressure or the number of patients achieving target drug
dose. Serum creatinine levels were normal at the onset of the
study, but increased slightly in patients receiving enalapril
alone (þ 2.3 mmol/l) and reduced in the group receiving
carvedilol alone (2.5 mmol/l).111
HF is either present at the initiation of chronic dialysis or
develops subsequently in one-quarter to one-third of patients
with ESRD and substantially impacts survival.112 In chronic
hemodialysis patients with established dilated cardiomyo-
pathy, carvedilol has been associated with improvements in
left ventricular size and function. After 1 year of treatment
with carvedilol, left ventricular ejection fraction increased
39%, and left ventricular systolic and diastolic volumes
decreased 16 and 6%, respectively, compared with no change
shown with placebo.12 By the end of the second year of
the trial, 49% fewer carvedilol-treated patients had died
compared with those receiving placebo (Po0.01).
Microalbuminuria is recognized marker of increased
cardiovascular risk in patients with CKD, hypertension,
and/or diabetes; progression to macroalbuminuria
(4300 mg/day) indicates presence of kidney disease. Carve-
dilol was compared with the b1-selective blocker atenolol in a
randomized, open-label study involving 140 patients with
mild-to-moderate essential hypertension.113 Despite an
equivalent reduction in blood pressure, carvedilol was
associated with a significantly greater reduction in urinary
albumin excretion. After 2 months, the proportion of
patients with urine albumin levels X10 mg/l (could not
verify unit) remained unchanged in the atenolol group, but
was reduced by 40% with carvedilol. Carvedilol has also been
shown to eliminate microalbuminuria in 58% of nondiabetic
hypertensive patients who had tested positive by dipstick
before the start of 3 months of treatment.114 In a multicenter
trial of 245 patients with mild-to-moderate essential
hypertension and microalbuminuria treated with carvedilol
for 6–12 weeks, there was a blood pressure-independent
reduction in urine albumin in 56% of patients; urine albumin
disappeared completely in 48% of the patients.115
A recent large-scale, randomized clinical trial compared
carvedilol and metoprolol tartrate added to a treatment
regimen containing a renin–angiotensin system antagonist in
1235 diabetic patients with established hypertension.116 After
5 months of maintenance therapy, blood pressure had
decreased to the same extent in both groups, yet the mean
urinary albumin/creatinine ratio of the carvedilol group had
decreased by 1%, whereas the albumin/creatinine ratio of the
metoprolol tartrate group increased by 2.5%. Of those
patients with trace protein loss (30 mg/g or less) at baseline,
47% fewer carvedilol-treated patients progressed to micro-
albuminuria (430 mg/gm/day) than those receiving meto-
prolol tartrate (P¼ 0.03).117 The study also confirmed
previous reports that carvedilol improves insulin sensitivity
and glycemic control while producing significantly fewer
proatherogenic changes in serum cholesterol and triglyceride
levels than b1-selective blockers.
116
Oxidative stress appears to be a blood pressure-indepen-
dent determinant of microalbuminuria in hypertensive
patients,118 and the antioxidant activity of carvedilol (free-
radical scavenging as well as sequestration of iron in ferric
ion-induced oxidation), may play an additive role in its
protection against glomerular damage leading to albumin-
uria.119
Nebivolol is a relatively new lipophilic b1-blocker
approved for hypertension that is devoid of intrinsic
sympathomimetic or membrane stabilizing activity but is
unique in that it has nitric oxide-mediated vasodilatory
effects. The drug does not significantly influence glucose or
plasma lipid metabolism and appears to have a protective
effect on left ventricular function. The most common adverse
events reported with this agent are similar to other
vasodilating b-blockers and includes headache, fatigue,
paraesthesias, and dizziness.120
The effects of this novel b-blocker on kidney function are
limited to animal models as of this writing. In two separate
studies, one in Sprague–Dawley rats nebivolol was shown to
increase both renal plasma flow and GFR.121–122 Additionally,
sodium and chloride excretion were increased in a dose-
dependent manner, as was potassium, albeit not dose-
dependent. The mechanism by which this increase in renal
plasma flow occurs is presumably through the 5-HT1A
receptor/NO pathway.121–122
CONCLUSION
CKD, with the frequently associated conditions of hyper-
tension, diabetes, and HF, is a state of overactivity of the SNS.
Antiadrenergic drugs play an important role in its manage-
ment. Antihypertensive regimens including b-blockers slow
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the deterioration of renal function as assessed by decreasing
GFR and worsening albuminuria. It is therefore deplorable
that b-blockers are still underutilized out of fear of adversely
affecting renal function and glycemic control.
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